Yaiza Senent

Abstract cGAS-STING signaling can promote antitumor immunity, and tumor cell STING is suppressed in a variety of cancer subtypes that resist immune checkpoint blockade. Although STING agonists have failed clinical trials, precision approaches targeting restoration of tumor cell STING expression have yet to be explored.

Keywords cholangiocarcinoma biliary tract cancer KRAS oncogene RAS(ON) multi-selective inhibitor targeted therapy therapy resistance drug combinations preclinical models Introduction The KRAS oncogene is one of the most broadly mutated oncogenes in humans and a key driver in lung, colorectal, and pancreatic cancer, the three most common causes of death by cancer in the US.1,2 KRAS mutations also occur in less prevalent, but equally fatal, cancers such as those of the biliary tract, esophagus,...